Inhibikase announced Dr. Scott Wasserman is joining its board and an incumbent director, Dennis Berman, is resigning. The move aims to bolster expertise as Inhibikase advances its Phase 3 trial of IKT-001 for Pulmonary Arterial Hypertension.